Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer
Pfizer and Astellas Pharma have announced positive topline results from the Phase 3 EMBARK trial […]
Matrivax Initiates Phase 1 Clinical Development of MVX01, a Novel Pneumococcal Vaccine Candidate
Vaccine development company Matrivax announces the start of its Phase 1 clinical study to assess […]
Invitae Appoints Dr. W. Michael Korn as Chief Medical Officer for Oncology
Invitae, a leading medical genetics company, has announced the appointment of Dr. W. Michael Korn, […]
Mitsubishi Tanabe Pharma America Announces More Than 10,000 People with ALS Treated with RADICAVA ORS® and/or RADICAVA®
Mitsubishi Tanabe Pharma America today announced that more than 10,000 people with amyotrophic lateral sclerosis […]
Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells
Propanc Biopharma, a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and […]
TrueBinding Granted Type B End-of-Phase 2 Meeting with FDA for Discussion of Accelerated Development Pathway for TB006 Alzheimer's Disease Treatment
TrueBinding, a clinical-stage biotherapeutic company creating new and exciting molecules for applications in neurodegenerative and […]
Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington's Disease
UCB, a global biopharmaceutical company, and Aitia, the leader in the application of Causal AI […]
Inspire Biotherapeutics Launches with Pre-seed Investment to Target Monogenic and Acquired Lung Diseases with Proprietary AAVenger Gene Therapy Platform
Inspire Biotherapeutics, an emerging biotech company with a mission to create life-saving gene therapies for […]
Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients
Syndax Pharmaceuticals, today announced that data from the Phase 1 portion of the ongoing Phase […]
DEM BioPharma Appoints Miriam Merad, M.D., Ph.D., to Scientific Advisory Board
DEM BioPharma, an immune-oncology company developing therapies that target signals on cancer cells and macrophages […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more